These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30358019)

  • 21. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus.
    Tsuchiya T; Ishida H; Tanabe T; Shimizu T; Honda K; Omoto K; Tanabe K
    Transplantation; 2013 Jul; 96(2):198-204. PubMed ID: 23792649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
    Stifft F; Undre N; van Hooff JP; Christiaans MH
    Ther Drug Monit; 2016 Aug; 38(4):456-62. PubMed ID: 27128604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
    Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
    Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations.
    Alloway R; Vanhaecke J; Yonan N; White M; Haddad H; Rábago G; Tymchak W; Diaz Molina B; Grimm M; Eiskjaer H; Karpf C; Undre N
    J Heart Lung Transplant; 2011 Sep; 30(9):1003-10. PubMed ID: 21493098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial.
    Wlodarczyk Z; Squifflet JP; Ostrowski M; Rigotti P; Stefoni S; Citterio F; Vanrenterghem Y; Krämer BK; Abramowicz D; Oppenheimer F; Pietruck F; Russ G; Karpf C; Undre N
    Am J Transplant; 2009 Nov; 9(11):2505-13. PubMed ID: 19681813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study.
    Cabello M; García P; González-Molina M; Díez de los Rios MJ; García-Sáiz M; Gutiérrez C; López V; Sola E; Burgos D; Hernández D
    Transplant Proc; 2010 Oct; 42(8):3038-40. PubMed ID: 20970603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily prolonged-release tacrolimus in de novo liver transplantation: a single center cohort study.
    Marubashi S; Wada H; Kobayashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Hepatogastroenterology; 2012 Jun; 59(116):1184-8. PubMed ID: 22172333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome.
    Han Y; Du SQ; Xiao HJ; Zhou Y; Ding J; Ding JJ; Cui YM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):807-813. PubMed ID: 29045960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
    Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
    Cross SA; Perry CM
    Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
    Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
    Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.
    Huppertz A; Bollmann J; Behnisch R; Bruckner T; Zorn M; Burhenne J; Haefeli WE; Czock D
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):899-907. PubMed ID: 33641238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations.
    Coilly A; Calmus Y; Chermak F; Dumortier J; Duvoux C; Guillaud O; Houssel-Debry P; Neau-Cransac M; Stocco J
    Liver Transpl; 2015 Oct; 21(10):1312-21. PubMed ID: 26264233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.